Background: The optimal implantation site of a new implantable cardiac monitor
| INTRODUCTION
The implantable loop recorder is a useful device to investigate potential cause(s) of unexplained syncope, 1, 2 or undiagnosed arrhythmias, [3] [4] [5] but challenges include patient discomfort and infectious risks. 6 Very recently, a smaller sized implantable loop recorder could be commercially available for clinical use named Reveal LINQ â (implantable cardiac monitoring [ICM] system) from Medtronic (Minneapolis, MN, USA). The reduced size simplifies the implantation procedure and has been associated with a decrease in patient discomfort. 6 The manufacturer's recommended implantation site is identical to that used to obtain optimal transthoracic echocardiography (TTE) windows. However, depending upon its size, the optimal implantation site is anatomically restricted due to the importance of acquiring a sufficient amplitude of electrical potential (AEP) of the R wave. Because the ICM may remain implanted for several months or even years, the decrement in TTE quality as a result of the ICM has the potential to impact clinical care and patient outcomes during the period of implantation.
Thus, we investigated 3 research questions with important clinical implications: (i) assessment of the optimal insertion sites and settings to achieve sufficient AEPs; (ii) whether the presence of an imitation ICM impacts TTE performance; and (iii) whether the quality of TTE data was different before and after placing the imitation ICM.
2 | ME TH ODS
| Subjects
We enrolled 18 healthy volunteers (10 male, 8 female) from age 23 to 63 (mean 45.3 AE 13.6 years) at the Hokkaido Cardiovascular
Hospital through advertisements. The study was conducted from May 8, 2017, to June 9, 2017. Written informed consent was obtained before commencement of the study.
| Measurements of R wave AEPs
As actual implantation was not permissible, we attached the thoracic electrodes to our subjects, distancing (37.7 mm) them proximal to the location in which an actual ICM would be implanted to create a clinically plausible simulation. Initially, 2 small electrodes were attached in the 4th intercostal space (ICS) positioned similarly to precordial leads V2 and V3 2 cm lateral to the left sternal border (Figure 1A: site A/setting a; A/a, the site and settings recommended by the manufacturer). To ascertain outcomes and TTE performance during implantation at alternative sites, we moved the electrodes caudally to the 5th ICS in the previously described parasternal position We measured the AEPs as follows:
1. Two small electrodes were attached in the way described above using a special measure (Figure 2 ), based on the actual site of the ICM.
2. Both electrodes were connected to a pacemaker programmer 2090W (Medtronic) with electrical cables ( Figure 3) ; then, AEPs were measured based on the site-setting combinations described above.
3.
The AEPs in all sites/settings were measured in supine, left lateral decubitus, right lateral decubitus, sitting, and standing positions.
4.
We defined a sufficient AEP based on a clinically significant R wave of ≥0.3 mV, and an AEP twice the amplitude of the T wave and P wave.
We measured AEPs in an apical position among an initial analysis of 3 subjects, but we opted to exclude further measurements in this position because of an inability to measure AEPs. The differences in echocardiographic data before and after imitation ICM placement at both sites were evaluated.
| Statistical analyses
We compared AEPs and echocardiographic data before and after imitation ICM placement using a paired t test. We also compared
AEPs between those achieved in the supine position relative to other positions using a paired t test. The difference in AEPs in the 3 site-setting combinations was analyzed by repeated-measures ANOVA. If a significant difference was observed, we performed a paired t test with the Bonferroni correction. We compared the extent of interference in TTE performance at sites A and B with
Fisher's exact test. In this analysis, we specified grade 1 or 2 as the presence of significant interference, and grade 0 as the absence of significant interference. Statistical analyses were performed using SPSS (SPSS Inc., Chicago, IL, USA), specifying statistical significance as P < .05.
3 | RESULTS Table 1 shows subjects' demographic and physical characteristics.
| Subjects' characteristics
One subject had a BMI < 18.5, and 3 subjects had a BMI > 25 (mean BMI 22.6 AE 3.0). All other study subjects' BMIs stayed within the normal range. Table 3 shows the grade of interference with TTE performance after placement of the imitation ICM in setting a, according to site. At site A, there was significant interference (P = .0006) in 14 of the 18 subjects (78%), but at site B in only 3 subjects (17%). Table 4 exhibits the echocardiographic data before and after placement of the imitation ICM. The end-diastolic dimension of the left ventricle was significantly decreased at site A, but not site B (P = .028). The end-systolic dimension, the spherical index of the left ventricle, and the left atrial dimension were not altered by placement of the imitation ICM at either site.
| AEP acquisition

| Influence on echocardiographic data after placement of the imitation ICM
| Patient discomfort
All the female subjects complained of discomfort after the imitation ICM was placed at site B, but not site A, likely related to the presence of a brassiere, the wire of which overlaid the imitation ICM.
| DISCUSSION
We obtained 3 important conclusions regarding the ideal implantation site and setting for ICM placement. First, the sham ICM implantation revealed that the B/a combination is optimal in both achieving a sufficient AEP in all positions and avoiding interference with TTE performance. Second, placement at site B created discomfort among female subjects due to the presence of a brassiere. Finally, setting b
should not be used due to insufficient AEP acquisition.
Very recently, a smaller sized implantable loop recorder may be commercially available for clinical use named Reveal LINQ â from
Medtronic to minimize patient discomfort and employment of a less invasive implantation process. 6 As size creates restrictions regarding the optimal implantation site(s) at which sufficient AEPs can be acquired, this development may have important clinical implications.
An important challenge of optimizing ICM implantation is the anatomic overlap with the location for obtaining data while conducting echocardiographic examinations during the period of implantation.
As ICMs often remain implanted for several months or years, interference with TTE performance is a potentially important demerit for patients during the period of implantation. 
| LIMITATIONS OF THE STUDY
This study was conducted using a small number of self-selected healthy volunteers at a single institution. We obtained data based on volunteers varying widely among characteristics, including age range.
Most of enrolled subjects had a BMI within the normal range. It is 
| CONCLUSIONS
Based on our small, but rigorously conducted study, we conclude that B/a is the optimal combination for ICM implantation. In addition, we report information regarding the extent and sources of patient discomfort, mostly relevant for females. Finally, we conclude that setting b is suboptimal due to a reduced ability to acquire sufficient AEPs.
DISCLOSURES
Medtronic provided an imitation of the ICM and a special measuring device to ascertain the distance between 2 electrodes to accurately approximate the distance between electrodes of an actual ICM.
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